Core Viewpoint - Blue Moon Group (06993) announced a share buyback of 372,000 shares for a total expenditure of HKD 1.0302 million, scheduled for March 30, 2026 [1] Group 1 - The company is engaging in a share repurchase program, indicating a strategy to enhance shareholder value [1] - The total amount allocated for the buyback is HKD 1.0302 million, reflecting the company's financial commitment [1] - The number of shares being repurchased is 372,000, which may impact the company's share price and market perception [1]

Group 1 - The core viewpoint of the articles highlights that China Resources Vientiane Life achieved a revenue of 18.022 billion yuan in 2025, representing a year-on-year growth of 5.1%, with core net profit increasing by 13.7% to 3.950 billion yuan [1] - The company declared a final dividend of 0.509 yuan per share and a special final dividend of 0.341 yuan per share, resulting in a total annual dividend of 1.731 yuan per share, which is a 12.7% increase year-on-year [1] - The commercial segment, known as "Vientiane Commercial," reported retail sales of 266 billion yuan in 2025, with a growth rate of 23.7%, outperforming the overall retail sales growth [1] Group 2 - By the end of 2025, Vientiane Commercial operated 135 shopping centers, with 54 centers ranking first in local market sales and 105 centers among the top three in their respective markets [1] - The company opened 14 new shopping centers in 2025 and successfully explored differentiated innovation tracks with projects like Vientiane Binhai Shopping Village and Xi'an MIXC AIR [1] - The third-party expansion strategy focused on key city TOD projects, signing 12 new projects with an average total construction area exceeding 100,000 square meters [1] Group 3 - In the office building sector, by the end of 2025, the company managed 223 office projects with a total area of 18.15 million square meters [2] - The integrated approach of "leasing + operation + property management" led to a double-digit growth in new leased area, with the average occupancy rate increasing by 3.6 percentage points to 77.2% [2] - Customer satisfaction reached 99%, indicating continuous improvement in operational quality [2]

Core Viewpoint - The company, Minshi Group, has received an upgrade in its MSCI ESG rating from BBB to A, effective from March 23, 2026, reflecting its ongoing progress in sustainable development management and efforts towards high-quality and sustainable growth [1][2]. Group 1: ESG Rating Upgrade - The MSCI ESG rating is a widely recognized sustainable development assessment system that evaluates companies based on environmental, social, and governance dimensions [1]. - The upgrade to A indicates external recognition of the company's ESG governance standards and actual achievements [2]. Group 2: Sustainable Development Initiatives - In 2025, under the leadership of the management team, the company will deepen its sustainable development initiatives, including a clear carbon neutrality roadmap and systematic emissions analysis [1]. - The company has introduced a quarterly ESG KPI assessment mechanism and launched a carbon data management platform to integrate ESG goals into its global operations [1]. Group 3: Governance and Transparency - The company has released several key ESG governance documents, such as the Human Rights Policy Statement and Responsible Minerals Policy Statement, enhancing transparency in information disclosure [2]. - A series of ESG workshops and targeted training programs have been organized for the management team, functional departments, product lines, and factories to strengthen internal capacity building in sustainable development [2]. Group 4: Future Outlook - The company aims to continue enhancing its ESG governance and performance while collaborating with customers, suppliers, and other business partners to promote a more sustainable and low-carbon industrial ecosystem [2].

Core Viewpoint - The company announced that its subsidiary, Shanghai Heyu Biomedical Technology Co., Ltd., has received FDA approval for the clinical trial application of its selective small molecule FGFR2/3 inhibitor ABSK061 for treating children with achondroplasia (ACH) [1] Group 1 - The FDA has granted permission for the IND of ABSK061, which is a significant milestone for the company [1] - The approval is complemented by the previously awarded Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) by the FDA, which will facilitate the overseas clinical development of ABSK061 [1]

Core Viewpoint - Huaxing Capital Holdings (01911) reported a net profit attributable to shareholders of RMB 101 million for the year ending December 31, 2025, marking a turnaround from losses in the previous year, with total revenue increasing by 37.19% to RMB 1.066 billion [1] Group 1: Investment Management Business - The investment management business continued to be a key pillar for the group's revenue growth and profit enhancement, with a stable asset management scale of RMB 28.4 billion at year-end [2] - The group distributed approximately RMB 2.5 billion to limited partners (LPs) during the reporting period, with five out of eleven main funds achieving a DPI (Distributions to Paid-In) ratio exceeding 100% [2] - The group realized approximately RMB 524 million in carried interest income in 2025, with cumulative carried interest realized reaching around RMB 1.3 billion [2] Group 2: Huaxing Securities Performance - Huaxing Securities reported revenue and net investment income of RMB 294 million, a year-on-year increase of 19%, while operating losses narrowed by 52% to approximately RMB 46 million [3] - Retail and brokerage business revenue grew by 55%, accounting for 43% of Huaxing Securities' total revenue, becoming a significant growth driver [3] - The number of registered users for the Duoduo Jin app reached approximately 570,000, a 47% increase year-on-year, with active customer numbers growing by 58% to around 310,000 [3]

Group 1 - AstraZeneca's global commercial vice president and team visited Alibaba Health to discuss the integration of digital health ecosystems and medical empowerment service models [1] - The collaboration aims to enhance disease management services through a digital platform that emphasizes professional capabilities and service upgrades [1] - A strategic cooperation agreement was signed to upgrade the collaboration model, focusing on integrating online medical empowerment with comprehensive health management [1][2] Group 2 - Alibaba Health is committed to creating a patient-centered full-cycle health service system, addressing the lack of continuous professional support in outpatient health management [2] - The partnership will combine AstraZeneca's expertise in disease management with Alibaba Health's digital outreach capabilities, providing a full-link professional support system for patients [2] - The collaboration aims to deliver high-quality healthcare services and fulfill both health and social value through continuous outpatient management solutions [2]

Core Viewpoint - The company, He Yu-B (02256), announced that its subsidiary, Shanghai He Yu Biopharmaceutical Technology Co., Ltd., has received FDA approval for the IND application of its selective small molecule FGFR2/3 inhibitor, ABSK061, aimed at treating achondroplasia in children [1] Group 1 - The IND approval from the FDA will accelerate the overseas clinical development process of ABSK061 [1] - The drug has previously been granted rare pediatric disease designation (RPDD) and orphan drug designation (ODD) by the FDA [1]

Core Viewpoint - AAC Technologies (02018) announced a share buyback plan, intending to repurchase 450,000 shares at a cost of HKD 15.159 million by March 30, 2026 [1] Group 1 - The company plans to execute the buyback to enhance shareholder value [1] - The total amount allocated for the buyback is approximately HKD 15.159 million [1] - The number of shares to be repurchased is 450,000 [1]

截至2025年末，普通股权一级资本较上年末增长10.9%，主要由2025年盈利带动。总资本较2024年末增 长9.2%。风险加权资产较2024年末下降7.5%，主要由于《巴塞尔协定三》最终改革方案于2025年1月1 日正式生效实施后，信贷风险和操作风险的风险加权资产下降。普通股权一级资本比率和一级资本比率 均为24.01%，总资本比率为25.98%。集团动态管控资本资源配置，努力提升资本回报，在满足监管要 求的基础下，确保业务可持续发展及努力实现股东回报的长期稳定增长。 截至2025年末，集团资产总额达港币44898.09亿元，较上年末增长港币2954.01亿元或7.0%。库存现金 及在银行及其他金融机构之结余及定期存放下降港币425.17亿元或7.0%，主要由于在中央银行之定期存 放减少。证券投资及其他债务工具上升港币2756.91亿元或18.9%，主要由于集团增持政府及金融机构债 券。贷款及其他账项上升港币388.70亿元或2.3%，其中客户贷款上升港币389.01亿元或2.3%。 中银香港(02388)发布2025年度业绩，提取减值准备前的净经营收入为港币770.19亿元，按年上升港币 57.66亿元或 ...

Group 1 - The company, China Biologic Products Holdings, announced a share buyback of 10 million shares at a cost of HKD 58.424 million on March 30, 2026 [1]